Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2007

View Archived Issues

New Integrity Disease Briefing highlights head and neck cancers

Preclinical and phase I data on activity of AT-1001 presented

Satraplatin improves pain and PSA responses in phase III trial

Vardenafil studies presented at European Association of Urology congress

LY-2076962, non-morphinan opioid receptor antagonist, evaluated in phase I study

Celsion files for SPA for ThermoDox

MEDI-545 begins clinical evaluation in psoriasis

Novartis signs agreement for branded interferon beta-1b

New therapeutic agents for thrombotic disorders disclosed in recent patent literature

Ethics approval for second phase IIa neuropathic pain study of ACV-1

EvoGenix achieves milestone in GSK collaboration for protein-based therapeutics

Zanaflu registered as brand name for chitosan gel

Recent patents report novel analgesic agents

CHR-2797 begins phase II for AML in elderly patients

Semafore's PI3K inhibitor studied in phase I for solid tumors

Arrowhead Research forms new nanomedicine subsidiary

New agents for treating neurological disorders disclosed in recent patents

Merck & Co. and Schering-Plough to develop new cholesterol lowering product

PF-184298 presented as clinical candidate by Pfizer

Phase III study of vilazodone in depression completes enrollment

European orphan drug designation for enzastaurin in DLBCL

orBec cleared for phase II study in prevention of GVHD

New selective androgen receptor modulator profiled at Merck

BioLineRx in-licenses new therapeutic candidates

Positive phase IIa results for DIO-902 in type 2 diabetes

Cephalon files for European approval of fentanyl effervescent buccal tablet

Modiodal launched in Japan

AZ-004 reduces agitation in schizophrenic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...